Active	Status	Sponsor type	Region	Phase	Filter
1 Active 9 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
oprozomib (ONX 0912) / Amgen
2013-001169-18: Oral Oprozomib in combination with oral dexamethasone in Relapsed and/or Refractory Multiple Myeloma	Not yet recruiting	1/2	128	Europe	Oprozomib, Dexamethasone, ONX 0912, H02AB02, Tablet, Fortecortin	Onyx Therapeutics, Inc., Onyx Therapeutics, Inc.	Relapsed and/or Refractory Multiple Myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04]